It has recently been reported that celastrol suppresses CRC via covalent targeting of ROS‐manipulating PRDX1 [28], indicating the potential of PRDX1 as a molecular target for cancer therapy. Single‐cell RNA‐sequencing datasets from CRC patients (GSE205506) provide a potential link between PRDX1 overexpression and resistance to anti‐PD‐1 immunotherapy. Here, PRDX1 is linked to colorectal carcinoma.